M1FG
AVDL

Mach-1 Financial Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Mach-1 Financial Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,067
Closed -$328K – 259
2025
Q2 		$328K Buy
+37,067
New +$326K 0.1% 183

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Mach-1 Financial Group's AVDL Position: Q3 2025 in Review

Mach-1 Financial Group sold out of Avadel Pharmaceuticals (AVDL) in Q3 2025, closing a stake of 37,067 shares — an estimated $328K sold.

Mach-1 Financial Group first reported a position in AVDL in Q2 2025 and held it in 1 quarter. The position peaked at $328K in Q2 2025. 188 funds tracked by Wall St. Rank hold AVDL as of Q3 2025.

  • Mach-1 Financial Group reported no remaining Avadel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 37,067 Avadel Pharmaceuticals shares in Q3 2025, an estimated $328K.
  • Mach-1 Financial Group first reported a position in Avadel Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's Avadel Pharmaceuticals position peaked at $328K in Q2 2025.
  • 188 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2025.

Based on Mach-1 Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.